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Serum N-Terminal Type III Procollagen Propeptide: An Indicator of
Growth Hormone Excess and Response to Treatment in Feline
Hypersomatotropism
S.V. Keyte, P.J. Kenny, Y. Forcada, D.B. Church, and S.J.M. Niessen
Background: N-terminal type III procollagen propeptide (PIIINP) is a biomarker of soft tissue proliferation. Hypersoma-
totropism (HS) is associated with soft tissue proliferation.
Hypothesis: Serum PIIINP is increased in cats with HS and decreases with eﬀective treatment, and may be an additional
tool in the diagnosis and treatment of feline HS.
Animals: Cats with uncomplicated diabetes mellitus (DM; n = 30) and with HS-induced DM (HSDM; n = 30). Pre- and post-
treatment samples were available from 5 cats undergoing radiotherapy (RT) and 16 cats undergoing hypophysectomy (HPX).
Methods: Retrospective and prospective cross-sectional study. Analytical performance of a serum PIIINP ELISA was
assessed and validated for use in cats. PIIINP and insulin-like growth factor 1 (IGF-1) radioimmunoassays (RIA) were per-
formed pre- and post-treatment in cats with DM and HSDM. PIIINP and IGF-1 were compared between cats treated by
RT and HPX.
Results: Serum PIIINP concentrations were signiﬁcantly higher (P < .001) in HSDM cats (median, 19.6 ng/mL; range,
1.7–27.9) compared to DM cats (median, 5.0 ng/mL; range, 2.1–10.4). A cut-oﬀ of 10.5 ng/mL allowed diﬀerentiation
between DM and HSDM cats with 87% sensitivity and 100% speciﬁcity (area under the curve [AUC], 0.91; 95% conﬁdence
interval [CI], 0.82-1). After RT, PIIINP increased signiﬁcantly (P = .043) with no signiﬁcant change in IGF-1 concentrations.
After HPX, serum PIIINP (P = .034) and IGF-1 concentrations (P < .001) decreased signiﬁcantly.
Conclusion and clinical importance: PIIINP concentrations are increased in cats with untreated HSDM compared to those
with DM, demonstrating the eﬀect of excess GH on soft tissue. PIIINP concentrations decreased after HPX in most HSDM
cats.
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Hypersomatotropism (HS), excess production ofgrowth hormone (GH) by a functional soma-
totrophic adenoma, carcinoma or hyperplasia of the
pituitary gland, and the resulting syndrome acromegaly
are thought to be relatively common among diabetic
cats.1–3 Feline HS now is hypothesized to cause diabetes
in as many as 1 in 4 diabetic cats.3 A subtle or initially
unremarkable phenotype and diﬃcult and expensive
diagnostic process likely have contributed to the previ-
ous underestimation of its prevalence.1,3,4 Given the
pulsatile nature of GH secretion and the absence of an
easily accessible commercial GH assay, a presumptive
diagnosis currently is most commonly based on mea-
surement of circulating GH-induced production of
insulin-like growth factor 1 (IGF-1), rather than GH
itself.1,2,4–10
Initial suspicion of HS mostly has been based on the
screening of poorly controlled diabetic cats for the pres-
ence of increased IGF-1 concentrations1 (>1000 ng/mL).
However, non-acromegalic diabetic cats can have
increased IGF-1 concentrations (false positive) and
newly diabetic acromegalic cats can have normal IGF-1
concentrations (false negative).1,2,4,11 More advanced,
expensive, and invasive diagnostic tests, speciﬁcally
intracranial imaging under sedation or general anesthe-
sia, are therefore often necessary to allow conﬁrmation
of the diagnosis.12 Nevertheless, this approach also can
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prove falsely negative in cats with microadenoma or
acidophilic hyperplasia.1,2 Deﬁnitive diagnosis of HS
therefore is made by pituitary gland histopathology.
This process involves hypophysectomy (HPX) or post-
mortem examination, which is not performed routinely.
Therefore, development of additional, easily accessible
tools for diagnosis of HS is desirable.
Earlier diagnosis and treatment could be facilitated by
additional diagnostic tests, improve chances of diabetic
remission13,14 and decrease the impact of excess GH on
the patient’s body.15 Development of markers other than
serum IGF-1 also would be beneﬁcial to understand the
wider impact of HS on the cat’s physiology and compare
the beneﬁcial eﬀects of various treatment modalities.
Indeed serum IGF-1 concentration merely reﬂects the
ability of GH to directly stimulate IGF-1 production
(mainly in the liver). However, IGF-1 production also is
inﬂuenced by other factors, including availability of por-
tal venous insulin, which in turn depends on remaining
beta-cell function or exogenous insulin provision.
Finally, serum IGF-1 concentration has been shown to
be a poor marker of treatment success after radiother-
apy (RT) in cats with diabetes and HS.16
Growth hormone stimulates bone and soft tissue
turnover resulting in some of the acromegalic changes
typical of chronic HS.17,18 Assessment of a marker that
reﬂects the tissue impact of HS is therefore of interest.
Collagen is synthesized with propeptides at both ends
of the molecule, and cleavage of these propeptides pro-
motes formation of collagen ﬁbrils and ﬁbrosis.19 The
propeptides are either retained in the matrix or released
into the circulation, and the latter can be measured in
serum. One such propeptide is N-terminal type III pro-
collagen propeptide (PIIINP), which has been shown to
correlate in a dose-dependent manner with serum con-
centrations of GH in humans.20,21 Indeed, serum
PIIINP concentrations consistently have been shown to
be increased in humans with active acromegaly and
decrease after successful treatment.22,23 Measurement of
PIIINP therefore represents an opportunity to assess a
diﬀerent aspect of the impact of HS and its treatment
than its glycemic impact, on which most clinicians focus
on when evaluating a cat with HS.
The aims of our study were therefore to: a) validate a
human N-terminal propeptide of collagen alpha-1 (III)
chain (PIIINP) enzyme-linked immunosorbent assay
(ELISA) for use in cats; b) describe and compare
PIIINP concentrations in cats with HS-induced diabetes
mellitus (HSDM) and primary diabetes mellitus (DM);
and, c) compare PIIINP as a measure of soft tissue
turnover after RT and HPX.
Materials and Methods
Study Population
The study included serum samples from 30 DM cats and 30
HSDM cats as deﬁned by the following criteria: DM—clinical
signs consistent with DM, evidence of pathologic hyperglycemia
and glucosuria, inappropriately high serum fructosamine concen-
tration, lack of evidence of insulin resistance (deﬁned as
>1.5 iu/kg/injection on a q12h protocol), low serum IGF-1
concentration (<600 ng/mL); and HSDM—diabetic cats (with a
history of DM and insulin treatment) with conﬁrmed HS based on
identiﬁcation of a pituitary lesion on intracranial imaging (pitu-
itary dorsoventral height >4 mm) and an IGF-1 concentration
>1000 ng/mL3 or histopathologic evidence of a somatotrophi-
noma. One HSDM cat undergoing HPX had an initial IGF-1 con-
centration >1000 ng/mL and a repeated IGF-1 concentration
<1000 ng/mL immediately before HPX. This cat was included in
the HSDM group based on pituitary histopathology conﬁrming
the diagnosis. The groups were matched by preferentially selecting
samples for age, sex, and breed (in that order), and by conﬁrming
absence of a statistical diﬀerence (Mann-Whitney U-test, Table 2).
Conﬁrmed HSDM cats that underwent RT or HPX with suﬃcient
residual serum available for analysis were recruited both retrospec-
tively and prospectively from the Acromegalic Cat Clinic from
May 2007 to May 2015.
Sample Collection
These samples, as well as additional samples from cats in the
treatment group, had been collected previously as part of an ongo-
ing, prospective diabetic cat screening project, as well as through
the Royal Veterinary College Acromegalic Cat Clinic, which diag-
noses and treats cats with HS. Samples from HSDM cats undergo-
ing treatment were collected from residual blood both
retrospectively and prospectively. All serum samples were stored at
80°C until analysis. The interval between therapeutic interven-
tion and sample procurement for measurement of posttreatment
IGF-1 and PIIINP concentrations varied because of owner avail-
ability. However, a minimum time period of 1 month was chosen
for all groups. The Ethics Committee of the Royal Veterinary Col-
lege approved collection of all samples.
Human N-Terminal Propeptide of Collagen Alpha-1
(III) and IGF-1 Measurement
A competitive ELISA kit for human N-terminal propeptide of
collagen alpha-1 [III] chain was validated.a The assay was per-
formed according to the manufacturer’s instructions at room
temperature.a In brief, 50 lL of sample or standard containing
PIIINP was added to each well, primed with monoclonal anti-
body speciﬁc to the N-terminal propeptide of collagen alpha-1
(III) chain, followed by addition of a ﬁxed amount of competing
biotin-labeled PIIINP. After a 1 h incubation, plates were
washed with provided solution, 100 lL avidin conjugated to
horseradish peroxidase added, incubated for 45 min, 90 lL
tetramethylbenzidine (TMB) substrate solution added, incubated
for another 20 min, and ﬁnally 50 lL sulfuric acid added. All
samples were analyzed within 5 min and in duplicate. Color
change was measured by spectrophotometric analysis at a wave-
length of 450 nm. The concentration of PIIINP was calculated
by comparing the measured optical density to the standard curve.
The standard curve consisted of diluted human PIIINP (concen-
trations of 0, 0.31, 0.62, 1.25, 2.5, 5.0, 10.0 and 20.0 ng/mL)
using zero standard. Where sample values fell outside of the
standard curve, they were diluted until they fell within the stan-
dard curve. The PIIINP concentrations were calculated by multi-
plying the concentrations obtained from intrapolation with the
corresponding dilution.
ELISA Validation
Parallelism with the standard curve was evaluated and con-
ﬁrmed by serial dilution of feline serum containing high PIIINP
concentrations using zero standard. Assay accuracy was further
evaluated by assessing recovery of serially mixing samples with
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high PIIINP concentration with those containing low PIIINP con-
centration (percentage mixtures: 100 : 0; 75 : 25; 50 : 50; 25 : 75;
0 : 100) and comparing expected with measured concentrations.
Assay precision was established by calculation of inter- and intra-
assay coeﬃcients of variation (CV). Intra-assay CV was deter-
mined by repeated measurement of 2 feline serum samples with
known low (4.1 ng/mL) and high (38.5 ng/mL) PIIINP concentra-
tions during the same assay run (at least 4 times) with the same
ELISA plate. Inter-assay CV was determined by repeated measure-
ment of PIIINP concentrations in 3 consecutive ELISA runs on
diﬀerent days with diﬀerent plates. The diﬀerent PIIINP concen-
trations were achieved by dilutions 1 : 1, 1 : 4, 1 : 8, 1 : 10 of a
serum sample from a HSDM cat to simulate dilutions likely
required to bring the HSDM cat samples onto the standard curve.
Aliquots of the dilutions were used in the 3 runs. The lower limit
of detection (LoD) was calculated by performing 12 consecutive
measurements of zero standard in the same ELISA and was
deﬁned as the mean plus 2 standard deviations.24
Impact of freeze-thaw cycles was assessed by creating aliquots
of residual serum samples from a single cat. The serum samples
were stored frozen at 80°C and underwent 3 cycles of thawing at
room temperature and refreezing. The impact of icterus, hemoly-
sis, lipemia and azotemia were not speciﬁcally assessed, but all
samples with macroscopic signs of hyperbilirubinemia, hemolysis,
or lipemia were excluded.
Serum IGF-1 concentrations were measured simultaneously in
all used samples, employing a previously validated RIA.1,3 For the
purpose of our study, concentrations in excess of 2000 ng/mL (up-
per LoD of the assay) were deﬁned as equal to 2000 ng/mL, and
concentrations <15 ng/mL as equal to 15 ng/mL (the assay’s lower
LoD).
Statistical Analysis
All analyses were performed using commercial statistical soft-
ware packages should be.b,c Data distributions were assessed by
visual assessment of histograms and the Shapiro-Wilk normality
test. Dilutional parallelism was evaluated by calculation of a cor-
relation coeﬃcient during linear regression. If PIIINP concentra-
tions were not normally distributed, nonparametric tests were
used and data presented as median and range. If data was nor-
mally distributed, parametric tests were used and data were pre-
sented as mean and standard deviation. Comparisons of data
between 2 groups were performed with the Mann-Whitney test.
For comparisons of data among multiple groups, the Kruskal-
Wallis ANOVA was used. Wilcoxon signed rank tests were used
for comparisons of IGF-1 and PIIINP concentrations within
groups (eg, pre- versus posttreatment). Correlations between vari-
ables were evaluated by calculation of Spearman’s rank correla-
tion coeﬃcient. Results were deemed signiﬁcant if P < .05. To
assess performance of PIIINP as a potential diagnostic biomar-
ker, a receiver-operating characteristic (ROC) curve was con-
structed.
Results
PIIINP Assay Validation
Parallelism with the standard curve was conﬁrmed
during serial dilution of feline serum containing high
PIIINP concentration with zero standard. A correlation
coeﬃcient of 0.98 was determined based on linear
regression (Fig 1A). Intra-assay coeﬃcients of variation
for high PIIINP concentration and low PIIINP concen-
trations were 7.3 and 7.8%, respectively. Inter-assay
coeﬃcients of variation for high PIIINP concentration
and low PIIINP concentrations are presented in
Table 1. Because of the inter-assay variability demon-
strated, all samples analyzed subsequently for compar-
ison (DM versus HSDM and pre- and posttreatment)
were performed during the same assay run and all sam-
ples were appropriately diluted. The lower LoD was
determined to be 0.7 ng/mL.
Repeated freeze-thaw cycles did not signiﬁcantly
aﬀect PIIINP concentrations (Kruskal-Wallis; P = .37).
Recovery studies performed by mixing high and low
concentration PIIINP samples at serial ratios (100 : 0,
75 : 25, 50 : 50, 25 : 75 and 0 : 100) showed an average
of 16% variability between expected and observed
PIIINP concentrations (Fig 1B).
Study Population
No statistically signiﬁcant diﬀerences in age, breed,
or sex between DM and HSDM cats were found. Cats
with DM had a median age of 133 months (range, 70–
198) and HSDM cats 120 months (range, 63–186). The
HSDM cats had signiﬁcantly higher body weight (mean,
5.93 kg; 1.32 versus mean, 4.77 kg; 1.64, P = .007);
(Table 2), insulin requirements (median, 1.4 iu/kg/injec-
tion (range, 0.5–4.5) versus 0.6 iu/kg/injection (range,
0.2–1.4), P < .005), and serum fructosamine concentra-
tion (median, 579 lmol/L (range, 214–910) versus
481 lmol/L (range, 218–1241), P = .007). None of the
HSDM cats in the study had unequivocal phenotypical
signs of acromegaly.
Serum PIIINP Concentrations in HSDM and DM
Cats
Serum PIIINP concentration did not correlate signiﬁ-
cantly with body weight when considering both groups
together (Spearman’s rho, P = .098) or when evaluating
both groups separately (Spearman’s rho; DM cats only
P = .59; HSDM cats, P = .79). Serum PIIINP concen-
trations were signiﬁcantly diﬀerent between HSDM cats
(median, 19.6 ng/mL; range, 1.7–27.9) and DM cats
(median, 5.0 ng/mL; range, 2.1–10.4; Mann-Whitney
U-test, P < .001; Fig 2). The area under the ROC curve
was 0.91 (95% CI, 0.8-1). Using a cut-oﬀ value of
10.5 ng/mL, PIIINP concentration had a sensitivity of
86.7% and speciﬁcity of 100% for diﬀerentiation
between DM and HSDM cats.
PIIINP after RT and HPX
Samples from 5 cats were recruited for comparison of
pre- and post-RT PIIINP concentrations. Post-RT sam-
ples were taken a median of 6 months after treatment
(range, 4–8 months). The IGF-1 concentrations did not
change signiﬁcantly post-RT in these cats with HSDM
(median pre, 1915 ng/mL; range, 1087–2000; median
post, 1263 ng/mL; range, 645–2000; Wilcoxon signed
rank test; P = .068; Fig 3C), whereas serum fruc-
tosamine concentration (median pre, 691 lmol/L;
range, 464–740; median post, 412 lmol/L; range, 298–
590; Wilcoxon signed rank test; P = .04; Fig 3B) and
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exogenous insulin dose decreased signiﬁcantly (median
pre, 1.30 IU/kg/injection; range, 0.77–3.05); median
post, 1.02 iu/kg/injection; range, 0.49–2.26; Wilcoxon
signed rank test; P = .03; Fig. 3A). The PIIINP concen-
tration increased signiﬁcantly post-RT in HSDM cats
(median pre-RT, 13.5 ng/mL; range, 10.5–19.8; median
post-RT, 15.0 ng/mL; range, 12.7–21.5; Wilcoxon
signed rank test; P = .043; Fig. 3D).
Samples from 16 HSDM cats that underwent HPX
were recruited. Post-HPX samples were taken a median
of 5 months after treatment (range, 1–13 months).
Serum IGF-1 concentration was signiﬁcantly decreased
post-HPX in HSDM cats (median pre-HPX,
1705 ng/mL; range, 590–2000; median post-HPX,
53 ng/mL; range, 15–1819; Wilcoxon signed rank test;
P < .001; Fig 4C). Serum fructosamine concentrations
and exogenous insulin dosages decreased signiﬁcantly
and are shown in Figures 4A and 4B. Serum PIIINP
concentrations also changed signiﬁcantly post-HPX
(median pre-HPX, 26.46 ng/mL; range, 14.59–99.61;
median post-HPX, 20.87 ng/mL; range, 8.7–34.42;
Wilcoxon signed rank test; P = .034; Fig 4D).
A
B
Fig 1. (A) Demonstration of dilutional parallelism of feline serum containing 9.5 ng/mL PIIINP (square) and the standard human sample
containing 20 ng/mL PIIINP (circle) diluted at 1:1 (shown for feline sample only), 1 : 2, 1 : 4, 1 : 8, and 1 : 16, respectively using zero stan-
dard. (B) Demonstration of spike and recovery expressed as a percentage when mixing diﬀerent samples of high and low PIIINP concentra-
tions by single measurements of diﬀerent ratios (100 : 0, 75 : 25, 50 : 50, 25 : 75, 0 : 100%). Recovery = (PIIINPmeasured/
PIIINPexpected) 9 100%.
Table 1. Inter-assay coeﬃcients of variation (%CV) of low (mean, 1.6 ng/mL; 1.8 ng/mL), intermediate (mean,
3.1 ng/mL), and high (mean, 8.6 ng/mL) PIIINP concentrations. The diﬀerent PIIINP concentrations were achieved
by dilutions 1 : 1, 1 : 4, 1 : 8, and 1 : 10 of serum of a HSDM cat.
Measured
concentration
1 (ng/mL)
Measured
concentration
2 (ng/mL)
Measured
concentration
3 (ng/mL)
Mean
concentration
(ng/mL)
Standard
deviation % CV
11.9 6.3 7.7 8.6 2.9 33.9
3.0 2.9 3.5 3.1 0.3 9.8
1.7 1.6 2.0 1.8 0.2 9.4
1.2 1.3 2.3 1.6 0.6 39.4
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Discussion
Serum PIIINP was found to be signiﬁcantly increased
in diabetic cats with HS compared to those without.
This observation emphasizes the marked body-wide
impact excess GH has in cats with HS beyond its
impact on insulin sensitivity, mirroring ﬁndings in
human acromegalic patients.17,23 Our study also sug-
gests that there is merit in exploring the potential for
serum PIIINP concentration as a diagnostic tool, along
with other established tools, showing a sensitivity of
86.7% and speciﬁcity of 100% when using a cut-oﬀ
value of 10.5 ng/mL for the diagnosis of HS. Finally,
the signiﬁcant decrease in both IGF-1 and PIIINP con-
centrations after HPX but not RT, further indicates the
necessity for studies into possible diﬀerences in eﬀective-
ness of these treatment modalities, beyond the ability to
ameliorate the HS-associated diabetic state.
Serum PIIINP concentration depends on the rate of
PIIINP production in the tissue of origin (mainly con-
nective tissue), release into the bloodstream and degra-
dation and elimination by the liver and kidneys.25 In
general, an ideal biomarker should be measurable in the
target species, stable, obtained easily and non-
invasively, have good sensitivity and speciﬁcity for the
disease process, and allow rapid turnaround of results.26
Unlike GH, PIIINP does not exhibit pulsatile secretion;
it also has a short half-life of 1 hour in circulation.27
The lack of commercial availability of a recombinant
feline PIIINP could have posed a limitation in its
assessment. However, good cross-reactivity between
feline and human PIIINP was expected because collagen
synthesis and metabolism have been shown to be well
preserved among mammals.28 The assay validation pro-
cess highlights the current level of accuracy and preci-
sion for the chosen ELISA. The stability of PIIINP, as
evidenced by the lack of freeze-thaw eﬀect in our study
and others,29 suggests the possibility of clinical use with
submission of samples in the practice setting. The
higher inter-assay CV for low and high concentrations
should be born in mind. For high concentrations, this
vulnerability could be circumvented by appropriate
dilution of the samples. The validation process could be
strengthened further by including a more extensive
range of concentrations for the purpose of CV calcula-
tions.
The signalment of cats was matched on the basis of
breed, sex, and age (in that order) to prevent impact of
signalment-associated confounding factors. Cats were
not matched on weight, and HSDM cats had signiﬁ-
cantly higher body weights. This observation could be
Table 2. Characteristics of cats with diabetes mellitus (DM), cats with hypersomatotropism and diabetes mellitus
(HSDM) including the subgroup of cats that underwent radiation therapy (RT) and hypophysectomy (HPX).
DM HSDM RT (Pre) RT (Post) HPX (Pre) HPX (Post)
Number (n) 30 30 5 5 16 16
Age (months) 133 (70–198) 120 (63–186) 106  25 – 126  46 –
Breed 23 DSH/4
DLH/1
Burmese/1
Siamese/1
Maine Coon
27 DSH/1
DLH/2 BSH
4 DSH/1
DLH
4 DSH/1
DLH
14 DSH/1
DSH/1 BSH
14 DSH/1
DSH/1 BSH
Sex 15 MN/13
FN/2 FE
23 MN/6
FN/1 ME
4 MN/1 FN 4 MN/1 FN 13 MN/3 FN 13 MN/3 FN
BW (kg) 4.77  1.64 5.93  1.32a 5.9 (3.92–9.1) 6.07 (5.44–10.1) 5.73  1.33 5.79  1.14
Insulin (iu/kg/inj) 0.60 (0.2–1.4) 1.40 (0.5–4.5)a 1.30 (0.77–3.05) 1.02 (0.49–2.26)b 1.40 (0.6–2.6) 0 (0–0.9)c
Fructosamine
(lmol/L)
481 (218–1241) 579 (214–910)a 691 (464–740) 412 (298–590)b 539 (380–743) 299 (197–676)c
IGF-1 (ng/mL) 331 (97–589) 1804 (1050–2000)a 1915 (1087–2000) 1263 (645–2000) 1705 (590–2000) 53 (15–1819)c
PIIINP (ng/mL) 5.0 (2.1–10.4) 19.6 (1.7–27.9)a 13.5 (10.5–19.8) 15.0 (12.7–21.5) 26.46 (14.59–99.61) 20.87 (8.7–34.42)c
aSigniﬁcant diﬀerence compared to the DM group.
bSigniﬁcant diﬀerence compared to the Pre-RT group.
cSigniﬁcant diﬀerence compared to the Pre-HPX group.
Fig 2. Serum PIIINP concentration in cats with diabetes mellitus
(DM) (circles) and hypersomatotropism and diabetes mellitus
(HSDM) (triangles). Median values are indicated by long horizon-
tal lines and interquartile ranges (IQR) are indicated by short
horizontal lines.
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because of the nature of HS, where excess GH and
IGF-1 can result in an increase in body mass. Neverthe-
less, no correlation could be detected between weight
and PIIINP in the cats of our study, making it unlikely
that diﬀerences in weight accounted for the diﬀerence in
PIIINP concentrations between the 2 groups. This
A
B
C
D
Fig 3. Insulin (A), fructosamine (B), IGF-1 (C), IGF-1 (C), and
PIIINP (D) concentrations before and after radiation therapy
(RT) for the 5 cats with HSDM that underwent RT. Dashed lines
connect pairs of observations before and after RT.
A
B
C
D
Fig 4. Insulin (A), fructosamine (B), IGF-1 (C), and PIIINP (D)
concentrations before and after hypophysectomy (HPX) for the 16
cats with HSDM that underwent HPX. Dashed lines connect pairs
of observations before and after HPX.
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conclusion is further substantiated by the fact that in
cats that showed an objective response to treatment of
HS (deﬁned as decreased IGF-1 concentration23 or
decrease in insulin requirement to control clinical signs),
this response led to a signiﬁcant decrease in PIIINP,
but not body weight. Body weight may be a poor mar-
ker of PIIINP-secreting tissues. Therefore, use of this
test alone, as compared to incorporating results of
feline body mass index calculation and dual-energy X-
ray absorptiometry (DXA) in all cases is a study limita-
tion. Another limitation is the lack of conﬁrmatory
pituitary histopathology for all HSDM cases (available
for 14/30 cats). Nevertheless, histopathology was avail-
able for 14/30 cats, and all 30 cats had macroadenoma
and increased IGF-1, which have been considered to be
suﬃcient for a clinical diagnosis of HS in both in
human and veterinary medicine.3,30 The insulin require-
ment of cats with conﬁrmed HS varied based on the
time of referral. Not all HSDM cases were insulin-resis-
tant (if deﬁned as an insulin requirement >1.5 IU/kg/in-
jection on a q12h protocol) at the time of assessment.
This observation is in agreement with recent literature
that describes conﬁrmed HSDM cases as having a wide
range of insulin requirements, and demonstrating that
insulin resistance does not necessarily need to be present
for a diagnosis of HSDM to be made.1,3,31
The PIIINP testing could have diﬀerent characteristics
to oﬀer as a screening test, which might enhance the
value of current IGF-1 screening. Indeed, non-
acromegalic diabetic cats can have increased IGF-1
concentrations, and newly diabetic acromegalic cats may
have normal IGF-1 concentrations. Lack of portal
venous insulin, not uncommon to diabetics, has been
implicated in the latter.11 Measurement of serum PIIINP
concentration may help identify cats with false-positive
or false-negative IGF-1 concentrations. Future studies
of these clinically challenging groups are warranted.
The occasional inaccuracy of serum IGF-1 concentra-
tion is also illustrated by the current study, where 1
HSDM cat in the HPX group, with histologically con-
ﬁrmed somatotrophinoma, had an IGF-1 concentration
>2000 ng/mL at time of initial diagnosis, but an IGF-1
concentration of 590 ng/mL just before HPX. In human
medicine, the variability of IGF-1 concentrations is rec-
ognized, but not completely understood. Some sugges-
tions include an eﬀect of insulin-like growth factor
binding proteins (IGFBP), or fragments of these, after
sample extraction that may interfere with the assay,
leading to falsely decreased or increased total IGF-1
concentration. In addition, the integrity of IGF-1 may
be altered in vitro, leading to inconsistencies in mea-
surement.32 Interestingly, the PIIINP concentration in
the sample described above (IGF-1 590 ng/mL) was
increased (26.6 ng/mL). In humans and cats, other dis-
ease states may aﬀect IGF-1 concentration, depending
on the type of assay used.33 Concurrent hepatopathies
decreased IGF-1 production, whereas renal failure and
solid tumors increased the concentration of IGFBP and
thus plasma IGF-1 concentration in humans.34 Hyper-
thyroidism increased and lymphoma decreased IGF-1
concentrations in cats in 1 study, suggesting that
interpretation of results becomes more diﬃcult if these
conditions are present in cats with DM.33 In turn, sev-
eral disease processes other than HS have been reported
to aﬀect PIIINP concentrations in humans, including
chronic hepatitis and ﬁbrosis,35,36 pulmonary hyperten-
sion,37 diabetic retinopathy,38 and hyperthyroidism.39
This observation emphasizes that PIIINP is by no
means a speciﬁc marker for HS or any other speciﬁc
disease but merely identiﬁes abnormalities in collagen
type III metabolism.
We aimed to exclude other such disease processes by
ensuring that thorough physical examinations and histo-
ries were performed and performing screening tests on
HSDM cats when appropriate, including serum total T4
concentration and abdominal imaging (eg, ultrasound
examinations or computed tomography), as well as by
following the progress of cats after their initial visits.
Two previous studies demonstrated use of PIIINP con-
centration in dogs.40,41 Future studies assessing the
impact of common disease processes and varying physio-
logical states in the cat also are indicated, but were
beyond the scope of our current study. Using diabetic
cats as a control group likely makes the ﬁndings of our
study stronger, given the known high prevalence of
comorbidities in diabetic cats,42 all with potential to
aﬀect PIIINP concentrations. Regardless, pretreatment
HSDM and DM cats still could be diﬀerentiated in most
cases on the basis of serum PIIINP concentration, sug-
gesting a strong correlation between substantially
increased PIIINP concentration and the eﬀects of excess
GH caused by HS.
As in previous studies, no signiﬁcant diﬀerence was
found in IGF-1 concentration pre- and post-RT in
HSDM cats.16,43 Ideally, more cats would have been
recruited into this group. However, given the fact that
HPX was available to owners as an equally expensive
alternative with greater success rate,d,e,5,44,45 this was
not possible. The low statistical power for cats undergo-
ing RT could have prevented detection of a signiﬁcant
diﬀerence after this therapeutic modality. In 2 of the 5
cats undergoing RT, we could not accurately measure
pre-RT IGF-1 concentration because it exceeded the
upper LoD (Fig 3C). The decrease in IGF-1 post-RT
therefore may have been more signiﬁcant than identiﬁed
in our study. Interestingly, PIIINP concentrations
increased signiﬁcantly after RT. This ﬁnding could indi-
cate a lack of consistent eﬃcacy of RT as a treatment
for HS. Indeed, even in cases which see diabetes
resolved after RT, ongoing soft tissue changes have
been observed.43 Alternatively, RT may be associated
with a late onset of treatment eﬀect.5,16 Cats therefore
may not have yet fully responded to RT, and GH con-
centration may still have been high, leading to ongoing
body-wide increased soft tissue turnover. This hypothe-
sis would be consistent with the fact that IGF-1 con-
centrations also did not decrease in these cats.
However, the cats did show a clinical response to RT
with all cats requiring less insulin after RT. A delay in
the maximum RT-response nevertheless could explain a
lack of change in PIIINP, but it does not explain why
concentrations actually increased. The latter could have
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been a consequence of RT-induced damage and result-
ing ﬁbrosis.
The human literature on serum PIIINP concentra-
tions after RT, however, does not indicate a consistent
demonstrable systemic increase. For instance, in women
receiving RT for breast cancer, when samples were
taken 10–96 months (mean 26) after RT, local skin col-
lagen turnover increased, although serum PIIINP con-
centrations did not.46 This is a period of time similar to
that in the studied cats. An additional study in humans
assessing serum PIIINP concentrations weekly during
and after a 5-week period of high-dose hemi-thorax
RT for pleural mesothelioma or nonsmall cell lung
cancer also did not identify consistently increased
PIIINP concentrations.47 Studies on the eﬀects of RT
on serum PIIINP concentrations in cats, aside from
our study, are not available. The PIIINP concentra-
tions might have decreased if samples had been taken
even later after RT. Indeed, in people with acrome-
galy, a decrease in IGF-1 can be identiﬁed up to
15 years after RT.48 Unfortunately, samples were only
available over a more limited time period and their
recruitment heavily relied on owners returning for the
suggested re-evaluations.
In contrast to RT, in people, serum, IGF-1 concentra-
tions rapidly decrease after HPX. Normalization of GH
and IGF-1 is used to assess biochemical control of acro-
megaly and acts as a predictor of long-term survival post-
surgery.30 Markers of collagen synthesis, including
PIIINP, and IGF-1 also have been shown to improve
after successful medical management of acromegaly in
humans with the GH receptor antagonist pegvisomant.22
The same would be expected with other treatment modal-
ities, including HPX. This improvement was encountered
in the HSDM cats that underwent HPX in our study,
where both IGF-1 and PIIINP concentrations decreased
signiﬁcantly in 12 of 16 cats. Alternative explanations for
the increase in PIIINP post-HPX in 4 of the 16 cats
include the eﬀect of surgical trauma and collagen forma-
tion from healing soft tissue and scar formation. These
4 cats had follow-up samples taken 1, 3, and 13 months
post-treatment, compared to a median of 5 months in
those with decreased PIIINP concentrations (range, 1–
10). In the human literature, serum PIIINP concentra-
tion has been shown to peak 2–3 weeks after orthope-
dic surgery and to remain increased for up to
60 days.49 In animal models, changes in serum PIIINP
concentration mirror collagen formation also support-
ing this hypothesis.50 Despite the increase in PIIINP
concentration, 3 of 4 of these cats no longer required
insulin treatment at the time of assessment. Diabetic
remission was common among the HPX group with 12
of 16 cats not requiring insulin treatment post-HPX,
compared to all 5 RT cats requiring insulin post-RT.
It is not known how some medications would aﬀect
serum PIIINP concentrations in cats. This consideration
could be relevant because all HPX cats received hor-
mone replacement after pituitary gland removal, which
included 2.5 mg hydrocortisone q24h,5,e 0.1 mg levothy-
roxine q24h,51,e and a decreasing amount of synthetic
antidiuretic hormone (desmopressin acetate, q8h
initially, then tapered)e. The eﬀect of these drugs on
serum PIIINP concentrations is unknown, but all are
used for physiologic replacement of lost endogenous
hormone function.
In conclusion, serum PIIINP concentrations are sig-
niﬁcantly increased in cats with HSDM compared to
those with DM, likely indicating increased soft tissue
turnover. The potential for serum PIIINP concentration
as an additional diagnostic biomarker for HS in cats
should be further evaluated. In addition, serum PIIINP
concentration appears to decrease after HPX.
Footnotes
a Human N-terminal propeptide of collagen alpha-1 (III) chain
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